Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas

British Journal of Cancer

Volumn 70, Issue 4, 1994, Pages 585-590

  Dix, B ^a   Robbins, P ^a   Carrello, S ^b   Housei, A ^a   Iacopetta, B ^a  

^a University Dept of Medicine   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ACCURACY; ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA POLYMORPHISM; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; BASE SEQUENCE; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DNA, NEOPLASM; GENE EXPRESSION; GENES, P53; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN P53; SUPPORT, NON-U.S. GOV'T;

EID: 0028129236     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1994.355     Document Type: Article

References (50)

1. ALLRED, D.C., CLARK, G.M., ELLEDGE, R., FUQUA, S.A.W., BROWN, R.W., CHAMNESS, G.C., OSBORNE, C.K. & MCGUIRE, W.L. (1993). Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl Cancer Inst., 85, 200–206.
2. BAAS, I.O., MULDER, J.W.R., OFFERHAUS, GJA., VOGELSTEIN, B. & HAMILTON, S.R. (1994). An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol., 172, 5–12.
3. BARTEK, J., BARTKOVA, J., VOJTESEK, B., STASKOVA, Z., LUKAS, J., REJTHAR, A., KOVARIK, J., MIDGLEY, C.A., GANNON, J.V. & LANE, D.P. (1991). Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene, 6, 1699–1703.
4. BARTON, C M., STADDON, S.L., HUGHES, C M., HALL, P.A., O’SULLIVAN, C., KLOPPEL, G., THEIS, B., RUSSELL, R.C.G., NEOPTOLEMOS, J., WILLIAMSON, R.C.N., LANE, D.P. & LEMOINE, N.R. (1991). Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br. J. Cancer, 64, 1076–1082.
5. BELL, S.M., SCOTT, N., CROSS, D., SAGAR, P., LEWIS, F.A., BLAIR, G.R., TAYLOR, G.R., DIXON, M.F. & QUIRKE, P. (1993). Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology, 104, 57–64.
6. BODNER, S.M., MINNA, J.D., JENSEN, S.M., DAMICO, D., CARBONE, D., MITSUDOMI, T., FEDORKO, J., BUCHAGEN, D.L., NAU, M.M., GAZDAR, A.F. & LINNOILA R.I. (1992). Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene, 7, 743–749.
7. BORRESEN, A.L., HOVIG, E., SMITH-SORENSEN, B., MALKIN, D., LYSTAD, S., ANDERSEN, T.I., NESLAND, J.M., ISSELBACHER, K.J. & FRIEND, S.H. (1991). Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc. Natl Acad. Sci. USA, 88, 8405–8409.
8. CAMPANI, D., CECCHETTI, D. & BEVILACQUA G. (1993). Immuno-cytochemical p53 detection by microwave oven heating of routinely formalin-fixed paraffin sections. J. Pathol., 171, 151–152.
9. CARON DE FROMENTEL, C. & SOUSSI, T. (1992). TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chrom. Cancer, 4, 1–15.
10. CUNNINGHAM, J., LUST, J.A., SCHAID, DJ., BREN, G.D., CARPENTER, H.A., RJZZA, E., KOVACH, J.S. & THIBODEAU, S.N. (1992). Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res., 52, 1974–1980.
11. DAVIDOFF, A M., HUMPHREY, P.A., IGLEHART, J.D. & MARKS, J R. (1991). Genetic basis for p53 overexpression in human breast cancer. Proc. Natl Acad. Sci. USA, 88, 5006–5010.
12. DIX, B.R., ROBBINS, P., SOONG, R., JENNER, D., HOVE, A.K., IACOPETTA, B.J. AND THE GENERAL SURGEONS AT SIR CHARLES GAIRDNER HOSPITAL (1994). The common molecular genetic alteration in Dukes’ B and C colorectal carcinomas are not short-term prognostic indications of survival. Int. J. Cancer (in press).
13. HOLLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B. & HARRIS, C.C. (1991). p53 mutations in human cancers. Science, 253, 49–53.
14. IACOPETTA, B., DIGRANDI, S., DIX, B., HAIG, C., SOONG, R. & HOUSE, A. (1994). Loss of tumour suppressor gene loci in human colorectal carcinoma. Eur. J. Cancer (in press).
15. ISOLA, J., VISAKORPI, T., HOLLI, K. & KALLIONIEMI, O P. (1992). Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl Cancer Inst., 84, 1109–1114.
16. JIKO, K., SASANO, H., ITO, K., OZAWA, N., SATO, S. & YAJIMA, A. (1993). Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus. Anticancer Res., 13, 305–310.
17. KERN, S.E., KINZLER, K.W., BRUSKIN, A., JAROSZ, D., FRIEDMAN, P., PRIVES, C. & VOGELSTEIN, B. (1991). Identification of p53 as a sequence-specific DNA-binding protein. Science. 252, 1708–1711.
18. KIKUCHI-YANOSHITA, R., KONISHI, M., ITO, S., SEKI, M., TANAKA, K., MAEDA Y., UNO, H., FUKAYAMA, M., KOIKE, M., MORI, T., SAKURABA, H., FUKUNARI, H., IWAMA T. & MIYAKI, M. (1992). Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res., 52, 3965–3971.
19. KOHLER, M.F., BERCHUCK, A., DAVTDOFF, A.M., HUMPHREY, P.A., DODGE, R.K., IGLEHART, J.D., SOPER, J.T., CLARKE-PEARSON, D.L., BAST, R.CJ, & MARKS, J.R. (1992). Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res., 52, 1622–1627.
20. KOHLER, M.F., KERNS, B. J.M., HUMPHREY, P.A., MARKS, J R., BAST, R.C.J. & BERCHUCK, A. (1993). Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet. Gynecol., 81, 643–650.
21. LANE, D.P. & CRAWFORD, L.V. (1979). T antigen is bound to a host protein in SV40-transformed cells. Nature. 278, 261–263.
22. LASSAM, N.J., FROM, L. & KAHN, H.J. (1993). Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res., 53, 2235–2238.
23. LEVINE, AJ., MOMAND, J. & FINLAY, C.A. (1991). The p53 tumour suppressor gene. Nature, 351, 453–456.
24. LINZER, D.I.H. & LEVINE, A.J. (1979). Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell, 17, 43–52.
25. LOTHE, R.A., FOSSLI, T., DANIELSEN, H E., STENWIG, A.E., NESLAND, J.M., GALLIE, B. & BORRESEN, A.-L. (1992). Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors. J. Natl Cancer Inst., 84, 1100–1108.
26. MAESTRO, R., DOLCETTI, R., GASPAROTTO, D., DOGLIONI, C., PELUCCHI, S., BARZAN, L., GRANDI, E. & BOIOCCHI, M. (1992). High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene, 7, 1159–1166.
27. MARKS, JR., DAVIDOFF, A.M., KERNS, BJ., HUMPHREY, P.A., PENCE, J.C., DODGE, R.K., CLARKE-PEARSON, D.L., IGLEHART, J.D., BAST, R.C.J. & BERCHUCK, A. (1991). Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res., 51, 2979–2984.
28. MOMAND, J., ZAMBETTI, G P., OLSON, D C., GEORGE, D. & LEVINE, A.J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237–1245.
29. MULERIS, M., SALMON, R.J., ZAFRANI, B., GIRODET, J. & DUTRILLAUX, B. (1985). Consistent deficiencies of chromosome 18 and of the short arm of chromosome 17 in eleven cases of human large bowel cancer: a possible recessive determinism. Ann. Genet., 28, 206–213.
30. NIGRO, J.M., BAKER, S.J., PREISINGER, A C., JESSUP, J.M., HOSTETTER, R., CLEARY, K., BIGNER, S.H., DAVIDSON, N., BAYLIN, S., DEVILEE, P., GLOVER, T., COLLINS, F.S., WESTON, A., MODALI, R., HARRIS, C.C & VOGELSTEIN, B. (1989). Mutations in the p53 gene occur in diverse human tumour types. Nature. 342, 705–708.
31. O’CONNELL, M.J., SCHAID, D.J., GANJU, V., CUNNINGHAM, J., KOVACH, J.S. & THIBODEAU, S.N. (1992). Current status of adjuvant chemotherapy for colorectal cancer. Cancer. 70, 1732–1739.
32. OLINER, J.D., PIETENPOL, J.A., THIAGALINGAM, S., GYURIS, J., KINZLER, K.W & VOGELSTEIN, B. (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 362, 857–860.
33. ORITA, M, SUZUKI, Y., SEKIYA, T. & HAYASHI, K. (1989). Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 5, 874–879.
34. PORTER, P.L., GOWN, A.M., KRAMP, S.G. & COLTRERA, M.D. (1992). Widespread p53 overexpression in human malignant tumors. Am. J. Pathol., 140, 145–153.
35. PURDIE, C.A., O GRADY, J., PIRIS, J., WYLLIE, A H. & BIRD, C.C (1991). p53 expression in colorectal tumors. Am. J. Pathol., 138, 807–813.
36. REMVIKOS, Y., TOMINAGA, O., HAMMEL, P., LAURENT-PUIG, P., SALMON, R.J., DUTRILLAUX, B. & THOMAS, G. (1992). Increased p53 protein content of colorectal tumours correlates with poor survival. Br. J. Cancer. 66, 758–764.
37. RODRIGUES, N.R., ROWAN, A., SMITH, M.E.F., KERR, IB., BODMER, W.F., GANNON, J.V. & LANE, D P. (1990). p53 mutations in colorectal cancer. Proc. Natl Acad. Sci. USA, 87, 7555–7559.
38. SANGER, F., NICKLEN, S. & COULSON, A.R. (1977). DNA sequencing with chain-terminating inhibitors. Proc. Natl Acad. Sci. USA, 74, 5463–5467.
39. SARNOW, P., HO, Y.S., WILLIAMS, J. & LEVINE, A.J. (1982). Adenovirus ElB-58kD tumour antigen and SV-40 large tumour antigen are physically associated with the same 54 kD cellular protein in transformed cells. Cell, 28, 387–394.
40. SCOTT, N., SAGAR, P., STEWART, J., BLAIR, G.E., DIXON, M.F. & QUIRKE, P. (1991). p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br. J. Cancer, 63, 317–319.
41. SILVESTRINI, R., BENINI, E., DAIDONE, M.G., VENERONI, S., BORACCHI, P., CAPPELLETTI, V., DIFRONZO, G. & VERONESE, U. (1993). p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J. Natl Cancer Inst., 85, 965–970.
42. SLINGERLAND, J.M., JENKINS, J R. & BENCHIMOL, S. (1993). The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EM BO J., 12, 1029–1037.
43. SOMERS, K.D., MERRICK, M.A., LOPEZ, M E., INCOGNITO, L.S., SCHECHTER, G.L. & CASEY, G. (1992). Frequent p53 mutations in head and neck cancer. Cancer Res., 52, 5997–6000.
44. STARZYNSKA, T., BROMLEY, M., GHOSH, A. & STERN, P.L. (1992). Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br. J. Cancer, 66, 558–562.
45. SUN, X. F., CARSTENSEN, J.M., ZHANG, H., STAL, O., WINGREN, S., HATSCHEK, T. & NORDENSKJOLD, B. (1992). Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet, 340, 1369–1373.
46. THOR, A.D., MOORE II, D.H., EDGERTON, S.M., KAWASAKI, E.S., REIHSAUS, E., LYNCH, H.T., MARCUS, J.N., SCHWARTZ, L., CHEN, L.-C., MAYALL, B.H. & SMITH, H.S. (1992). Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl Cancer Inst., 84, 845–855.
47. THORLACIUS, S., BORRESEN, A.-L. & EYFJORD, J.E. (1993). Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res., 53, 1637–1641.
48. VOGELSTEIN, B., FEARON, E.R., KERN, S.E., HAMILTON, S R., PREISINGER, A C., NAKAMURA, Y. & WHITE, R. (1989). Allelotype of colorectal carcinomas. Science, 244, 207–211.
49. WYNFORD-THOMAS, D. (1992). p53 in tumour pathology: can we trust immunocytochemistry? J. Pathol, 166, 329–330.
50. YAMAGUCHI, A., KUROSAKA, Y., FUSHIDA, S., KANNO, M., YONEMURA, Y., MIWA, K. & MIYAZAKI, I. (1992). Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer, 70, 2778–2784.